Method of treatment

Details Method of treatment Method of treatment

A - Human Necessities

61

K

A61K 31/41 (2006.01) A61K 31/415 (2006.01) A61K 31/4178 (2006.01) A61K 31/4196 (2006.01) A61K 31/4745 (2006.01) A61K 31/505 (2006.01) A61K 31/506 (2006.01) A61K 31/513 (2006.01) A61K 31/519 (2006.01) A61K 31/5415 (2006.01)

Patent

CA 2445913

This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1- [(2'-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazolecarboxylic acid and 3-(2'- (tetrazol-5-yl)-1,1'-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4,5- b]pyridine, or pharmaceutically acceptable salts thereof are useful.

L'invention porte sur un procédé de prévention des maladies rénales au stade final de patient dont le rein fonctionne mal consistant à utiliser un antagoniste de l'angiotensine II tel que le candesartan, le cilexetil, l'éprosartan, l'irbesartan, le losartan, le tasosartan, le telmisartan, le valsartan, l'acide 2-butyl-4-chloro-1-[(2'-tétrazol-5-yl)biphényl-4-yl)méthyl]imidazolecarboxylique, et la 3-(2'-(téetrazol-5-yl)-1,1'-biphén-4-yl)méthyl-5,7-diméthyl-2-éthyl-3H-imidazo[4,5-b]pyridine, ou leurs sels pharmacocompatibles.

Affiliated with

Also associated with

Rating

Method of treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1569242